Liquidia Corp (LQDA): Results of Operations and Financial Condition
Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations for revenue trajectory, cash burn versus profitability, and the pace of L606 pivotal execution based on the disclosed sales, earnings, cash balance, and R&D/SG&A changes.
Market read
The filing provides fresh, decision-relevant datapoints: sharp sequential YUTREPIA sales growth, consecutive profitability, and a higher cash balance, alongside rising R&D and SG&A for commercialization and L606.
What to watch
R&D and SG&A increased meaningfully, and the filing references ongoing YUTREPIA-related litigation, both of which can cap upside despite strong top-line momentum.
Liquidia Corporation Reports Second Quarter 2026 Financial Results
YUTREPIA product sales, net reached $170.4 million, net income was $74.7 million, and non-GAAP adjusted EBITDA was $96.3 million. The release also reported a $61.4 million increase in cash and cash equivalents compared to the first quarter of 2026, while highlighting ongoing litigation risk and rising commercial and development spending.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product sales, netGAAP | $170.4 million | 31% | $163.9 million |
| Service revenue, netGAAP | $1.3 million | – | $1.0 million decrease |
| Cost of product salesGAAP | $10.8 million | – | $10.6 million |
| Research and development expensesGAAP | $17.2 million | – | $11.2 million or 185% |
| Selling, general and administrative expensesGAAP | $57.4 million | – | $18.6 million or 48% |
| Total other expenses, netGAAP | $3.8 million | – | $0.3 million decrease |
| Income tax expenseGAAP | $7.0 million | – | – |
| Net incomeGAAP | $74.7 million | – | – |
| Net income per basic shareGAAP | $0.84 per basic share | – | – |
| Net income per diluted shareGAAP | $0.74 per diluted share | – | – |
| Adjusted EBITDAnon-GAAP | $96.3 million | – | – |
| Cash and cash equivalentsother | $284.2 million | increase of $61.4 million compared to the first quarter of 2026 | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| YUTREPIA product sales, netThe increase of $163.9 million was due to higher volume of YUTREPIA sales. | $170.4 million | 31% | $163.9 million |
| Service revenue, netService revenue, net was related to the promotion agreement with Sandoz, Inc. pursuant to which the company shares profits from the sale of Treprostinil Injection in the United States. The decrease was primarily due to the impact of unfavorable gross-to-net adjustments. | $1.3 million | – | $1.0 million decrease |
What drove it
- YUTREPIA net product sales of approximately $170.4 million were up 31% from the first quarter of 2026.
- The company received approximately 5,900 unique patient prescriptions and started more than 5,000 patients on treatment since launch in June 2025, as of July 31, 2026.
- Prescription-to-start conversion remained strong above the 85% level as previously reported.
- Total prescribers increased to more than 1,100 since launch, with more than 30% having prescribed YUTREPIA to at least 5 patients.
- The inhaled category has grown almost 40% since launch, according to the Chief Executive Officer.
- The company is progressing 10 clinical studies supporting YUTREPIA and L606 across known and new indications for inhaled treprostinil.
Concerns
- Service revenue, net declined primarily due to unfavorable gross-to-net adjustments.
- Research and development expenses increased primarily due to L606 program expenses, YUTREPIA research and development activities, personnel expenses, and an L606 development milestone.
- Selling, general and administrative expenses increased to support YUTREPIA commercialization, including higher personnel, stock-based compensation, commercial, and consulting expenses.
- The company states that its ability to maintain YUTREPIA approval and continue commercialization remains subject to ongoing litigation in which United Therapeutics is seeking injunctive relief.
What to watch
- Sustained YUTREPIA adoption, prescription-to-start conversion, prescriber expansion, and product-sales volume.
- The impact of gross-to-net adjustments on service revenue, net.
- Commercial spending and headcount growth supporting YUTREPIA commercialization.
- Progress of the open-label L606 study and Re-Spire, the global pivotal placebo-controlled efficacy study for PH-ILD.
- The timing and outcomes of YUTREPIA-related litigation, including the request for injunctive relief.
Balance sheet and cash flow
- Cash and cash equivalents totaled $284.2 million as of June 30, 2026, compared to $190.7 million as of December 31, 2025.
- The company reported an increase in cash and cash equivalents of $61.4 million compared to the first quarter of 2026.
Analysis
Liquidia reported a sharp expansion in YUTREPIA product sales, net, to $170.4 million for the three months ended June 30, 2026, compared with $6.5 million in the prior-year period. The company attributed the $163.9 million increase to higher YUTREPIA sales volume. The release also stated that YUTREPIA net product sales were up 31% from the first quarter of 2026. Commercial adoption indicators included approximately 5,900 unique patient prescriptions, more than 5,000 patients started on treatment, more than 1,100 prescribers, and prescription-to-start conversion above the 85% level as of July 31, 2026.
The sales increase supported a fourth consecutive quarter of increasing profitability. Liquidia recorded GAAP net income of $74.7 million, or $0.84 per basic share and $0.74 per diluted share, compared with a net loss of $41.6 million in the prior-year quarter. It also reported positive non-GAAP adjusted EBITDA of $96.3 million. Service revenue, net was $1.3 million, down from $2.3 million, with the decline primarily attributed to unfavorable gross-to-net adjustments under the Sandoz promotion arrangement for Treprostinil Injection.
Costs rose alongside the commercial launch and pipeline investment. Cost of product sales increased to $10.8 million due primarily to higher YUTREPIA sales volume. Research and development expense rose to $17.2 million, driven principally by a $7.0 million increase for L606, a $2.0 million increase in YUTREPIA research and development activities, higher personnel costs, and a $1.0 million L606 development milestone. Selling, general and administrative expense increased to $57.4 million, reflecting personnel, stock-based compensation, and commercial and consulting expenses, partly offset by lower YUTREPIA-related litigation fees.
Liquidity improved during the period. Cash and cash equivalents totaled $284.2 million as of June 30, 2026, compared with $190.7 million as of December 31, 2025, and the company cited a $61.4 million increase in cash and cash equivalents compared to the first quarter of 2026. Total other expenses, net were $3.8 million, while income tax expense was $7.0 million. The company attributed the lower other expense versus the prior-year quarter primarily to higher money market balances, offset by higher borrowings under its revenue interest financing agreement.
The release did not provide quantitative forward financial guidance. Operationally, management emphasized further YUTREPIA evidence generation and the advancement of L606, including site activation and enrollment in Re-Spire. The principal disclosed risk remains ongoing litigation involving United Therapeutics, which Liquidia states could affect its ability to maintain YUTREPIA approval and continue commercialization if injunctive relief is obtained.
Management, verbatim
We are pleased by the sustained adoption of YUTREPIA as the inhaled prostacyclin of choice. The inhaled category has grown almost 40% since launch, and YUTREPIA has captured an ever-increasing share of that growth. We are building on that momentum by strengthening the clinical evidence for YUTREPIA in PAH and PH-ILD patients transitioning from other therapies, and advancing studies in new indications that may broaden its impact. Having reset the bar for tolerability and dose flexibility with YUTREPIA, we are excited to have begun site activation and enrollment in Re-Spire, our pivotal study for L606, which we believe can raise that bar even further, beyond any therapy currently available or in development.
Dr. Roger Jeffs, Chief Executive Officer
Not in the filing
stated, not guessed- Total revenue was not printed as a separately labeled line item.
- Gross profit and gross margin were not reported.
- Operating income or loss was not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Debt balance was not reported.
- Share repurchases and dividends were not reported.
- Quantitative forward revenue, gross-margin, operating-expense, tax-rate, or other financial guidance was not provided.
- Prior-quarter values were not printed for most reported income-statement metrics.
- A non-GAAP adjusted EBITDA reconciliation was not included in the supplied filing text.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is Liquidia’s SEC 8-K (Item 2.02) with Q2 2026 financial results and operating highlights for YUTREPIA and the L606 program.
Ticker impact
Liquidia reported Q2 2026 results, including YUTREPIA net product sales of about $170.4M and net income of $74.7M.
Near-term bias higher as traders focus on sustained profitability and accelerating product sales, offset by higher R&D and litigation overhang.
The filing discloses large sequential sales growth, positive adjusted EBITDA, and a cash increase versus year-end, plus ongoing investment for the L606 pivotal program.
Market effects
Reinforces the commercial viability of inhaled treprostinil formulations in PAH and PH-ILD, potentially supporting sentiment for respiratory vascular biopharma.
Limited direct regional spillover; primarily US small/mid-cap biotech sentiment.
Modest, as the update is company-specific though it references global pivotal work for L606.
Counterpoint
Profitability may be heavily dependent on YUTREPIA ramp and could face volatility if growth slows or gross-to-net adjustments worsen.
Key entities
- companyLiquidia Corporation
NASDAQ-listed biopharmaceutical company reporting Q2 2026 financial results and YUTREPIA commercial metrics.
- productYUTREPIA (treprostinil) inhalation powder
Commercial product whose Q2 2026 net product sales and prescription/start metrics are driving profitability.
- pipeline_programL606 (liposomal treprostinil inhalation suspension)
Investigational extended-release treprostinil program, with site activation and enrollment in the Re-Spire pivotal study referenced.
- partnerSandoz, Inc.
Referenced via a promotion agreement that shares profits from Treprostinil Injection sales in the US.
- financing_counterpartyHealthCare Royalty Partners IV, L.P.
Referenced in connection with revenue interest financing and related borrowings.
